Strategic Pricing Intern
Genmab
Summary
The Strategic Pricing Intern will support pricing and contracting strategy across Genmab's US portfolio, helping advance the team's work to demonstrate the value of Genmab's medicines to payers, providers, and patients. Part of US Market Access, Strategic Pricing collaborates with colleagues across Market Access, Finance, Public Affairs & Policy, Global Market Access, and Legal to inform pricing decisions, develop payer and provider contracts, manage gross-to-net performance, and assess the business implications of federal and state policy developments.
Job description
Job Overview
The Strategic Pricing Intern will support pricing and contracting strategy across Genmab's US portfolio, helping advance the team's work to demonstrate the value of Genmab's medicines to payers, providers, and patients. Part of US Market Access, Strategic Pricing collaborates with colleagues across Market Access, Finance, Public Affairs & Policy, Global Market Access, and Legal to inform pricing decisions, develop payer and provider contracts, manage gross-to-net performance, and assess the business implications of federal and state policy developments.
What You'll Do
- Building and testing pricing and contracting scenario models in Excel.
- Analyzing rebate performance and gross-to-net drivers, including the impact of rebates, discounts, and other deductions on net revenue.
- Researching competitor pricing and contracting dynamics.
- Supporting analyses of federal and state pricing policies, including the Inflation Reduction Act (IRA), Medicaid, 340B, and price transparency requirements.
- Gathering and summarizing data, conducting literature and policy research, and preparing slides and materials for team meetings, internal governance, and leadership discussions.
- The intern will work with the team to define summer objectives and present key findings and recommendations at the end of the internship.
Required Qualifications, Capabilities And Skills
- Currently pursuing a degree in Economics, Finance, Business, Health Policy, Public Health, or a related field
- Strong quantitative and problem-solving skills, with proficiency in Excel and familiarity with PowerPoint
- Excellent attention to detail and strong written and verbal communication skills
- Ability to work independently and navigate ambiguous or open-ended questions
- No prior pharmaceutical experience required; curiosity about how medicines are priced and paid for in the U.S. is essential
Preferred Qualifications, Capabilities And Skills
- Coursework in health economics, health policy, pharmaceutical economics, or corporate finance.
- Prior internship or project experience in life sciences, healthcare consulting, a payer or PBM, or healthcare-focused investment research.
- Basic familiarity with how US drugs are reimbursed, such as the difference between pharmacy-benefit and medical-benefit drugs, or gross-to-net concepts like rebates and discounts.
- Awareness of current drug pricing policy debates, such as the Inflation Reduction Act, Medicaid rebates, 340B, or most-favored-nation pricing.
General Intern Information – Date/Location/Schedule
Internships will take place over 10 weeks from June – August 2027. This role will be based in Princeton, NJ and operate on a required hybrid schedule – 3 days in the office and 2 days remote per week. This role is not eligible for work visa sponsorship at the time of the application or in the future.
Requirements
- Currently pursuing a degree in Economics, Finance, Business, Health Policy, Public Health, or a related field
- Strong quantitative and problem-solving skills
- Proficiency in Excel
- Familiarity with PowerPoint
- Excellent attention to detail
- Strong written and verbal communication skills
- Ability to work independently and navigate ambiguous or open-ended questions
- Curiosity about how medicines are priced and paid for in the U.S.
Benefits
- Hybrid Schedule (3 days onsite)
- 10-Week Internship
Company overview
Genmab is a leading international biotechnology company headquartered in Copenhagen, Denmark, specializing in the development and commercialization of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has established itself as a pioneer in antibody technology with its proprietary DuoBody, HexaBody, and DuoHexaBody platforms. Genmab's innovative approach focuses on creating next-generation antibody-based therapies that target specific cancer cells while minimizing damage to healthy tissues. The company has several marketed products including DARZALEX (daratumumab) for multiple myeloma, which has become a cornerstone treatment in hematological malignancies. Genmab's pipeline includes numerous clinical-stage candidates targeting various cancers, leveraging its expertise in antibody engineering to develop novel immunotherapies. The company collaborates with major pharmaceutical partners worldwide and maintains a strong commitment to advancing cancer treatment through cutting-edge science and patient-focused innovation.